AIM: To evaluate the impact of moderately hypofractionated postoperative radiotherapy (RT) in prostate cancer (PCa). MATERIALS AND METHODS: The data of 304 surgically resected PCa patients were analyzed. One hundred and five patients underwent adjuvant RT (aRT), 77 early-savage RT (esRT), and 123 salvage RT (sRT). Biochemical relapse-free survival (BRFS), progression-free survival (PFS) and toxicity were analyzed. A propensity score matching (PSM) was performed to account for potential confounders between aRT and esRT groups. RESULTS: The median follow-up was 33 months. Three-year BRFS and PFS were 82 and 85.2%, respectively, in the overall population. At the multivariate analysis, Gleason score and hormone therapy were factors independently correlated with BRFS and PFS. After PSM, there was no difference in BRFS and PFS between aRT and esRT patients. Severe toxicity was represented by grade 3 urinary incontinence (3.5%) and urgency (1%), and aRT correlated with increased any-grade acute toxicity. Severe grade 3 gastrointestinal late toxicity occurred in 1.3% of cases. CONCLUSION: Postoperative moderately hypofractionated RT achieved acceptable disease control rate and demonstrated no increased or unexpected toxicity. Future prospective studies should evaluate the role of postoperative RT in patients with unfavorable disease characteristics.
AIM: To evaluate the impact of moderately hypofractionated postoperative radiotherapy (RT) in prostate cancer (PCa). MATERIALS AND METHODS: The data of 304 surgically resected PCa patients were analyzed. One hundred and five patients underwent adjuvant RT (aRT), 77 early-savage RT (esRT), and 123 salvage RT (sRT). Biochemical relapse-free survival (BRFS), progression-free survival (PFS) and toxicity were analyzed. A propensity score matching (PSM) was performed to account for potential confounders between aRT and esRT groups. RESULTS: The median follow-up was 33 months. Three-year BRFS and PFS were 82 and 85.2%, respectively, in the overall population. At the multivariate analysis, Gleason score and hormone therapy were factors independently correlated with BRFS and PFS. After PSM, there was no difference in BRFS and PFS between aRT and esRT patients. Severe toxicity was represented by grade 3 urinary incontinence (3.5%) and urgency (1%), and aRT correlated with increased any-grade acute toxicity. Severe grade 3 gastrointestinal late toxicity occurred in 1.3% of cases. CONCLUSION: Postoperative moderately hypofractionated RT achieved acceptable disease control rate and demonstrated no increased or unexpected toxicity. Future prospective studies should evaluate the role of postoperative RT in patients with unfavorable disease characteristics.
Authors: Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford Journal: J Urol Date: 2009-01-23 Impact factor: 7.450
Authors: Christopher C Parker; Noel W Clarke; Adrian D Cook; Howard G Kynaston; Peter Meidahl Petersen; Charles Catton; William Cross; John Logue; Wendy Parulekar; Heather Payne; Rajendra Persad; Holly Pickering; Fred Saad; Juliette Anderson; Amit Bahl; David Bottomley; Klaus Brasso; Rohit Chahal; Peter W Cooke; Ben Eddy; Stephanie Gibbs; Chee Goh; Sandeep Gujral; Catherine Heath; Alastair Henderson; Ramasamy Jaganathan; Henrik Jakobsen; Nicholas D James; Subramanian Kanaga Sundaram; Kathryn Lees; Jason Lester; Henriette Lindberg; Julian Money-Kyrle; Stephen Morris; Joe O'Sullivan; Peter Ostler; Lisa Owen; Prashant Patel; Alvan Pope; Richard Popert; Rakesh Raman; Martin Andreas Røder; Ian Sayers; Matthew Simms; Jim Wilson; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes Journal: Lancet Date: 2020-09-28 Impact factor: 79.321
Authors: Paul Sargos; Sylvie Chabaud; Igor Latorzeff; Nicolas Magné; Ahmed Benyoucef; Stéphane Supiot; David Pasquier; Menouar Samir Abdiche; Olivier Gilliot; Pierre Graff-Cailleaud; Marlon Silva; Philippe Bergerot; Pierre Baumann; Yazid Belkacemi; David Azria; Meryem Brihoum; Michel Soulié; Pierre Richaud Journal: Lancet Oncol Date: 2020-10 Impact factor: 41.316
Authors: Andrew Kneebone; Carol Fraser-Browne; Gillian M Duchesne; Richard Fisher; Mark Frydenberg; Alan Herschtal; Scott G Williams; Chris Brown; Warick Delprado; Annette Haworth; David J Joseph; Jarad M Martin; John H L Matthews; Jeremy L Millar; Mark Sidhom; Nigel Spry; Colin I Tang; Sandra Turner; Kirsty L Wiltshire; Henry H Woo; Ian D Davis; Tee S Lim; Maria Pearse Journal: Lancet Oncol Date: 2020-10 Impact factor: 41.316